Louise Frederika Kooij Sells 39,816 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 39,816 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $32.62, for a total transaction of $1,298,797.92. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $794,394.86. This trade represents a 62.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, January 28th, Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Down 1.0%

Shares of NASDAQ NAMS opened at $31.12 on Friday. The firm’s 50-day moving average price is $35.05 and its 200-day moving average price is $31.31. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The company has a market cap of $3.53 billion, a PE ratio of -15.18 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on NAMS shares. Leerink Partners reiterated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Stifel Nicolaus upped their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. HC Wainwright started coverage on shares of NewAmsterdam Pharma in a report on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Royal Bank Of Canada boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $47.00.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently modified their holdings of NAMS. Jennison Associates LLC lifted its position in shares of NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in NewAmsterdam Pharma during the 2nd quarter valued at approximately $595,000. Franklin Resources Inc. lifted its holdings in NewAmsterdam Pharma by 30.6% in the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after purchasing an additional 78,300 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after purchasing an additional 490,656 shares during the period. Finally, Maverick Capital Ltd. grew its holdings in NewAmsterdam Pharma by 178.8% during the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock valued at $27,742,000 after buying an additional 982,405 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.